Ivan Gergel becomes SVP, Drug Development & Chief Medical Officer at Nektar Therapeutics

Joins the company from Endo Pharmaceuticals

Nektar Therapeutics, a biopharmaceutical company developing novel pain and cancer therapeutics, has appointed Ivan Gergel as Senior Vice President, Drug Development & Chief Medical Officer. Gergel will have responsibility for the company's clinical strategy and activities, including direct supervision of clinical research, clinical operations, medical affairs, regulatory affairs, and drug safety and surveillance.

Gergel brings more than 25 years of pharmaceutical leadership and drug development experience to Nektar. From 2008 to 2014 he was Executive Vice President, Research & Development of Endo Pharmaceuticals and Chief Scientific Officer.

Prior to joining Endo, he was Senior Vice President of Research and Development at Forest Laboratories. Before this he was a senior leader at SmithKline Beecham where he was in charge of the US clinical team responsible for the development and commercial support of Paxil, which is approved to treat depression, OCD, panic disorder, social phobia and generalized anxiety disorder.

Robert Medve, Nektar's former Senior Vice President and Chief Medical Officer, left the company on 16 May.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now